Wolfe Research Reiterates Peerperform Rating on Alnylam Pharmaceuticals (ALNY)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to Wolfe Research Reiterates Peerperform Rating on Alnylam Pharmaceuticals (ALNY)

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiranā–¼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

August 30, 2024 6:00 AM EDT

In the Overall Population, Achieved 28% Reduction in Primary Composite of All-Cause Mortality and Recurrent Cardiovascular Events, and 31% and 36% Reductions in All-Cause Mortality During the 33-36-Month Double-Blind Period and up to Month 42, Respectively

In the Monotherapy Population, Reduced Composite Primary Endpoint by 33% and All-Cause Mortality up to Month 42 by 35%

Strong Trends of Additive Efficacy on Top of Tafamidis Across Primary and Secondary Endpoints

Demonstrated Statistically Significant Benefits on Multiple Measures of Disease Progression

Encouraging Safety and Tolerability Profile, Consistent with Established Profile... More